N4P has provided an update on its Nuvec® optimisation programme and proof of concept work involving COVID-19. Interestingly, delays imposed by the Pandemic lockdown presented an opportunity for the Group to explore a new initiative regarding Nuvec® ’s potential as an oral delivery system.
Research on the Group’s proprietary silica nanoparticles indicates that their unique spiky structure could provide a significant competitive advantage compared to existing, established routes of administration for vaccines (such as by injection) that are already in use.
In order to now demonstrate and verify this potential, N4P has now commissioned additional work by its contract research organisation (‘CRO’), Evotec Internation Gmbh (‘Evotec’), to undertake preliminary in vitro studies with a view to establishing that it can be optimised to transfect both murine intestinal cells and also human gastrointestinal mucosal/epithelial cells.
Such an outcome is likely to rapidly attract new interest from various ongoing COVID-19 and other vaccine development programmes that could benefit from oral administration.
Read More N4Pharma_6_7_2020_FINAL_BG.pdf
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to N4 Pharma plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned